SAN DIEGO, Feb. 25, 2011/PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced a series of changes within its senior management team to take effect March 31:
- Carlos Riva, currently Director, President and Chief Executive Officer, will be retiring from his position at the Company. He will continue to be available to the Company as a consultant for a period of time.
- James Levine, currently Executive Vice President and Chief Financial Officer, will be promoted to President and Chief Executive Officer, succeeding Carlos Riva. He will also be elected to the Company's Board of Directors.
- Jeffrey Black, currently Senior Vice President and Chief Accounting Officer, will be promoted to Chief Financial Officer. He will continue to report to Levine.
- Janet Roemer will continue as Chief Operating Officer and will report to Levine.
"This is an exciting time for Verenium and I am very pleased to have the opportunity to continue to partner with Janet, Jeff and the rest of our team as we focus on realizing Verenium's vision of building the next leading industrial enzymes company," said James Levine, President and Chief Executive Officer Designate of Verenium. "On behalf of the Company and our Board of Directors, I'd also like to recognize the many contributions Carlos made in his time here and wish him well with his future plans."
About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.